医薬品の結晶形を変換する新しい戦略
Jian Tian1, Scott J Dalgarno, Jerry L Atwood
1Department of Chemistry, University of Missouri-Columbia, Columbia, Missouri 65211, United States.
Journal of the American Chemical Society
|January 7, 2011
まとめ
ネットワーク材料は,ガスが誘発した変容を経験し,製薬用結晶形を変換することができます. この方法はエネルギー節約を提供し,クラリトロマイシンやランソプラゾールなどの薬剤の複雑な合成課題を回避します.
科学分野:
- マテリアルサイエンス 材料科学
- クリスタログラフィーです.
- 医薬品科学 医薬品科学とは
背景:
- ネットワーク材料は,強度を示し,ガス吸収のような外部刺激に反応します.
- 有機固体における長距離秩序の維持は,弱い分子間力により困難である.
- 製薬の製造には,しばしば複雑な合成と精製のステップが伴う.
研究 の 目的:
- 医薬品におけるガス誘発の結晶形変換を実証する.
- 安定した薬剤ポリモルフを生成するためのエネルギー効率の良い,簡素化された方法を探求する.
- 特定の薬物物質に関連する合成上の困難に対処するために.
主な方法:
- 固体変容の刺激としてガス吸附/脱吸収を利用する.
- 運動ソルバットとゲストフリー形態の熱力学的に安定したポリモルフへの変換を調査する.
- この方法をよく知られている医薬品:クラリトロミシンとランソプラゾールに適用します.
主要な成果:
- クラリトロマイシンの運動形態のガス誘発による変容により,安定したポリモルフに変化し,エネルギーが大幅に節約されます.
- 繊細なランソプラゾール溶酸塩を,複雑な合成手順を回避して,販売されている薬物物質に成功裏に変換した.
- ガス刺激下での容易および軽度の固体変容の実証.
結論:
- ガス誘発変換は,薬用ポリモルフ製造のための非常に効率的で費用対効果の高い代替案を提供します.
- このアプローチは,特に敏感な薬物物質の製造プロセスを簡素化します.
- この発見は,医薬品製造技術の進歩に大きく影響を与えます.
関連する概念動画
Crystal Growth: Principles of Crystallization
Crystallization is a phase transformation process in which crystals are precipitated from a supersaturated solution or formed from other sources. During crystallization, atoms or molecules arrange themselves into a well-defined, rigid crystal lattice to minimize energy.
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent – the...
Initiating crystallization involves manipulating the concentration of the solute and the temperature of the solution. Since crystal growth occurs when the ratio of concentration and solubility of the solute in the solvent – the...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Recrystallization: Solid–Solution Equilibria
Recrystallization is a purification technique used to separate impurities from solid compounds. In this technique, no chemical reactions occur. Instead, it exploits physical properties only, specifically, the solubility differences between the desired compound and impurities, either at a single temperature or at different temperatures, and under other selected conditions. The solid-solution equilibrium (solubility equilibrium) of each component in the solution represents a binary phase...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...


